Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa DoseConnect in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL)
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides
- Focus Pharmacodynamics
- Sponsors Sorrento Therapeutics
- 08 Jul 2022 Planned End Date changed from 31 Aug 2022 to 27 Mar 2024.
- 08 Jul 2022 Planned primary completion date changed from 31 Jul 2022 to 29 Jan 2024.
- 08 Jul 2022 Status changed from not yet recruiting to recruiting.